Eosinophilic asthma is treated with a layered approach, starting with inhaled corticosteroids and stepping up to biologic injections when standard therapy isn’t enough. It’s one of the most treatable forms of severe asthma because the specific immune pathway driving it can now be targeted with precision. The key is identifying the eosinophil-driven inflammation (typically a blood eosinophil count of 300 cells per microliter or higher, confirmed on at least two occasions) and matching treatment intensity to how well your symptoms respond.
Inhaled Corticosteroids: The First Line
Inhaled corticosteroids are the foundation of treatment for eosinophilic asthma because they directly suppress the type of airway inflammation that eosinophils cause. At moderate doses, they can reduce blood eosinophil levels by about 23% and sputum eosinophils by as much as 76%. This translates to fewer flare-ups, less airway reactivity, and reduced need for a rescue inhaler.
The dose-response benefit continues up to a moderate-high range. Beyond that, the returns diminish and the risk of side effects increases. For many people with eosinophilic asthma, doctors will adjust the inhaled corticosteroid dose based on eosinophil counts over time, not just symptoms alone. This strategy has been shown to reduce exacerbations even in patients who already feel well-controlled. Most people also use a long-acting bronchodilator alongside their inhaled corticosteroid, delivered through a single combination inhaler.
If your asthma stays poorly controlled on high-dose inhaled therapy, that’s the signal to evaluate whether a biologic medication should be added rather than simply increasing the steroid dose further.
Biologic Injections That Target Eosinophils
Biologics have transformed treatment for people whose eosinophilic asthma doesn’t respond well enough to inhalers. These are injections, given either at a clinic or self-administered at home, that block specific molecules in the immune chain responsible for producing or activating eosinophils. Several are now available, each targeting a slightly different point in the inflammatory pathway.
IL-5 Pathway Blockers
Interleukin-5 (IL-5) is the main signal your body uses to produce and activate eosinophils. Two biologics work by neutralizing this signal directly. Mepolizumab is given as a 100 mg injection under the skin once every four weeks. Reslizumab is delivered intravenously, typically at a clinic, on the same four-week schedule. Both reduce blood eosinophil counts dramatically and cut exacerbation rates in people with persistently high eosinophils.
A third option, benralizumab, takes a different approach. Instead of blocking the IL-5 molecule, it attaches to the IL-5 receptor on eosinophils and flags them for destruction by the immune system. This nearly eliminates circulating eosinophils. After three initial monthly doses, benralizumab is given once every eight weeks, which means fewer injections over time.
IL-4/IL-13 Blocker
Dupilumab blocks two related immune signals, IL-4 and IL-13, that drive both eosinophilic inflammation and allergic responses in the airways. It’s particularly useful if you also have nasal polyps, eczema, or elevated allergic markers alongside your asthma. It’s injected every two weeks.
TSLP Blocker
Tezepelumab works further upstream than the other biologics. It blocks a protein called thymic stromal lymphopoietin (TSLP), which is released by the cells lining your airways at the very start of the inflammatory cascade. By intercepting this early signal, it reduces eosinophils, allergic antibodies, and several other inflammatory markers simultaneously. It’s approved as an add-on treatment for severe asthma in people 12 and older, and it’s notable because it can help patients across different inflammatory profiles, not just those with high eosinophils.
Choosing the Right Biologic
The choice between biologics depends on your blood eosinophil level, whether you have overlapping allergic conditions, how often you’re flaring, and your preference for injection frequency. People with higher eosinophil counts (300 or above) tend to see the strongest responses from IL-5 pathway blockers. Those with a mixed allergic and eosinophilic picture may do better with dupilumab or tezepelumab. Your doctor will likely trial one biologic for several months before assessing whether to continue or switch.
Why Oral Steroids Are a Last Resort
Oral corticosteroids like prednisone are powerful at suppressing eosinophilic inflammation, and they’re still used for acute flare-ups. But long-term daily use carries serious risks that accumulate even at low doses. People taking less than 5 mg of prednisone daily are 2.5 times more likely to develop steroid-related complications than those not on oral steroids. At doses of 5 mg or more, the odds of infections roughly double and bone and muscle problems increase at a similar rate.
The cumulative toll is striking. One year of daily treatment at just 5 mg raises the likelihood of weight gain by about 60%, sleep problems by 45%, mood disturbances by 40%, and skin bruising by 40%. At 12.5 mg per day, those numbers climb further: 75% for weight gain, 60% for sleep disruption, and 55% for mood problems. The risk of osteoporosis at high cumulative doses is more than 12 times that of someone not taking oral steroids. Cataracts, high blood sugar, and bone fractures all become meaningfully more likely.
This is precisely why biologics have been such an important addition to treatment. One of their primary goals is to get patients off daily oral steroids, or at least reduce the dose substantially. If you’re currently taking oral corticosteroids for asthma control, a biologic that effectively manages your eosinophilic inflammation can often make tapering possible.
Bronchial Thermoplasty
Bronchial thermoplasty is a procedure done through a bronchoscope (a thin tube passed into the airways) that uses controlled heat to reduce the excess smooth muscle in the airway walls. Thickened airway muscle is one of the structural changes that makes severe asthma hard to control, and the procedure aims to reduce airway constriction at its source.
Real-world data from a large post-approval study showed meaningful long-term results five years after the procedure: a 45% reduction in severe exacerbations, 73% fewer emergency department visits, and 70% fewer hospitalizations. Interestingly, people with higher baseline blood eosinophils appear to be the best responders. It’s typically reserved for adults whose asthma remains uncontrolled despite maximum medical therapy, including biologics.
Managing Environmental Triggers
Eosinophilic asthma is driven by immune overactivity, and environmental exposures can amplify that response. Allergens are particularly important because they can directly fuel the eosinophilic pathway. Dust mite proteins (found in their body parts and droppings), mold spores, cockroach debris, and pet dander from dogs, cats, and rodents are all established triggers. Reducing exposure through allergen-proof bedding covers, regular cleaning to minimize dust accumulation, mold remediation, and keeping pets out of bedrooms can lower the overall inflammatory burden on your airways.
Irritants matter too, even if they don’t cause allergic reactions directly. Secondhand smoke contains over 4,000 substances and can both trigger and worsen asthma episodes. Nitrogen dioxide from gas stoves and heaters increases airway reactivity, and studies link even low-level exposure to more emergency visits for respiratory problems. Household chemical irritants, including cleaning products, paints, adhesives, air fresheners, and pesticides, can provoke reactions at sufficient concentrations. Wood smoke from fireplaces and stoves is another source of fine particles that aggravate the lungs.
Trigger avoidance won’t replace medication, but it reduces the frequency and severity of flare-ups, which can make the difference between needing more aggressive treatment and staying well-controlled on your current regimen.
What a Treatment Plan Looks Like Over Time
Treatment for eosinophilic asthma is stepped and ongoing. You’ll start with (or continue) inhaled corticosteroids, usually combined with a long-acting bronchodilator. If that isn’t enough to prevent exacerbations or you’re relying on oral steroids, your doctor will check your blood eosinophil count and other inflammatory markers to determine which biologic is the best fit. Once you start a biologic, expect a trial period of at least four to six months to gauge its effectiveness.
Blood eosinophil counts can be monitored over time to help guide dose adjustments to your inhaled corticosteroid, and to confirm that your biologic is doing its job. The goal is to reach a point where you’re free of daily oral steroids, experiencing minimal flare-ups, and using your rescue inhaler rarely. Many people with eosinophilic asthma achieve well-controlled disease with the right combination, but it often takes some iteration to get there.